TC BioPharm Shares Are Trading Higher After the Company Announced the Execution of a Non-binding Letter of Intent as Part of Its M&A Strategy Aimed at Expanding Its Therapeutic Platform and Leveraging NK Cells in Treating Both Solid Tumors and Other Indications
TC BioPharm的股价走高，此前该公司宣布执行一份不具约束力的意向书，这是其并购战略的一部分，旨在扩大其治疗平台并利用NK细胞治疗实体瘤和其他适应症